The Africa Centres for Disease Control and Prevention requested $18 million in urgent funding on Tuesday, June 30, 2026, to support experimental Ebola treatment trials [1].
These funds are critical for the Democratic Republic of Congo, where the agency aims to deploy clinical trials in Bunia. Without immediate financial support, the Africa CDC said that delays could jeopardize the containment of the current outbreak [1].
The request focuses on the ability to test and administer experimental drugs in a high-risk environment. The agency said the funding is necessary to ensure that the medical response keeps pace with the spread of the virus in the affected region [2].
Bunia has become a focal point for these efforts as health officials work to stabilize the situation. The Africa CDC is coordinating with local authorities to implement the trials, but the lack of immediate capital remains a primary obstacle to the timeline [2].
Effective containment of Ebola requires rapid intervention and the application of the most current medical research. The agency said that the $18 million [1] would allow for the procurement of materials, and the staffing of trial sites necessary to evaluate the efficacy of new treatments.
“Africa CDC requested $18 million in urgent funding to support experimental Ebola treatment trials.”
The request highlights the precarious nature of funding for emergency medical research in Central Africa. By linking funding directly to the ability to contain an active outbreak, the Africa CDC is emphasizing that the window for effective intervention is narrow, and that financial bottlenecks can lead to higher casualty rates during viral surges.
